The High-Throughput Screening (HTS) Core carries out target- and phenotype-based screens of small- molecule libraries. The HTS core will support the activities of twelve CF-related screening projects, including correctors and potentiators of ?F508-CFTR, and various CF-relevant ion transport and inflammation targets. The instrumentation available for screening includes a fully automated screening platform with liquid handling and two plate readers, and two separate plate readers with stackers. Plate-readers provide fluorescence, polarization, absorbance, and luminescence readout. Functions of the Core include compound storage and handling, assay design and validation, assay execution, and data analysis. Core resources also include HPLC, LC/MS, and NMR instrumentation for compound quality control. The Core also carries out optimization of validated initial `hits' (active compounds) by screening commercially available analogs. Further `hit-to-lead' development is done on individual projects in consultation with the Synthesis Core (Core C). Having operated the HTS Core for the past 9 years, the Core established practical procedures for efficient and cost-effective compound screening, quality control, and hit-to-lead optimization.
The High-Throughput Screening Core carries out target- and phenotype-based screens of small-molecule libraries in order to identify new drug candidates for cystic fibrosis therapy. The functions of the Core include compound storage and handling, assay design and validation, assay execution and data analysis.
|Sun, Dingyuan I; Tasca, Alexia; Haas, Maximilian et al. (2018) Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. Cells Tissues Organs :1-14|
|Bhakta, Nirav R; Christenson, Stephanie A; Nerella, Srilaxmi et al. (2018) IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med 197:313-324|
|Smith, Alex J; Verkman, Alan S (2018) The ""glymphatic"" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? FASEB J 32:543-551|
|Duan, Tianjiao; Smith, Alex J; Verkman, Alan S (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294|
|Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena et al. (2018) Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1. J Med Chem 61:3209-3217|
|Tradtrantip, Lukmanee; Felix, Christian M; Spirig, Rolf et al. (2018) Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 133:345-353|
|Phuan, Puay-Wah; Veit, Guido; Tan, Joseph-Anthony et al. (2018) ?F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 23:823-831|
|Verkman, Alan S; Yao, Xiaoming; Smith, Alex J (2018) The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. J Cell Mol Med 22:2039-2040|
|Tradtrantip, Lukmanee; Yao, Xiaoming; Su, Tao et al. (2017) Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol 134:35-44|
|Tradtrantip, Lukmanee; Jin, Bjung-Ju; Yao, Xiaoming et al. (2017) Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol 969:239-250|
Showing the most recent 10 out of 276 publications